Kailera Prices $625m IPO, One of the Largest Biotech Offerings Since Moderna 2018
Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings since Moderna’s $604m debut in 2018.
The 39 million shares started trading on Nasdaq under “KLRA” on April 17. Underwriters hold a 30-day option on another 5.86 million shares at $16, which would bring an additional $92.8m into Kailera’s coffers. Net proceeds per the S-1 were expected at $458.7m; the upsized deal closed that gap considerably.
What does the buyer actually get? Ribupatide, Kailera’s lead obesity asset, comes in two forms: an injectable running through the three-trial KaiNETIC programme and a once-daily oral pill entering Phase III. Kailera’s allocating $650m to the injectable programme through Q2 2028 and $150m to oral development. Both assets were in-licensed from Jiangsu Hengrui Pharmaceuticals and target the ex-China obesity market, which Eli Lilly and Novo Nordisk currently dominate.
The pipeline doesn’t stop there. KAI-7535, a small-molecule GLP-1 receptor agonist pill, is mid-stage. KAI-4729, a “triple G” agonist, is early.
The Bain-backed company launched in October 2024 with a $400m Series A. Eighteen months later, it’s public and it’s spending. Whether ribupatide can carve out room against Lilly and Novo on an ex-China label is the question $625m just bought Kailera time to answer.
Diana Kowalski
